Siddhant H. Tripathi

Siddhant H. Tripathi

Auto-generated profile, based on publicly available information

Siddhant H. Tripathi

Department of Otolaryngology University of Cincinnati College of Medicine Cincinnati Ohio USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2020 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
PDF file
JBJohn V. Bosso
John V. Bosso
TLTran B. Locke
Tran B. Locke
Edward C KuanEdward C Kuan
Edward C Kuan
STSiddhant H. Tripathi
Siddhant H. Tripathi
KIKevin I. Ig‐Izevbekhai
Kevin I. Ig‐Izevbekhai
NANithin D. Adappa
Nithin D. Adappa

1 March 2021 in Allergy and Asthma Proceedings
Verified
Journal Article
Open access
ASAuddie M. Sweis
Auddie M. Sweis
TLTran B. Locke
Tran B. Locke
KIKevin I. Ig-Izevbekhai
Kevin I. Ig-Izevbekhai
TLTheodore C. Lin
Theodore C. Lin
AKAnkur Kumar
Ankur Kumar
JBJohn V. Bosso
John V. Bosso
Background: Aspirin therapy and/or type 2 (T2) biologics are used in the management of aspirin-exacerbated respiratory disease (AERD). Objective: To identify the number of patients with AERD who tolerated aspirin therapy, yet due to persistent symptoms, incorporated T2 biologic management. Methods: A retrospective review was performed between July 2016 and June 2019. Patients with AERD and who underwent endoscopic sinus surgery (ESS), aspirin desensitization (AD), and at least 6 months of aspirin therapy (ATAD) after AD, and who remained biologic-naive up through this timepoint were included in the study. Introduction of a T2 biologic while on ATAD was the primary outcome. The secondary outcome was a change in a validated patient-reported outcome measure for chronic rhinosinusitis score between the postoperative predesensitization timepoint, and the 6-month postdesensitization timepoint, presented as means and compared by using the Student's t-test. Results: A total of 103 patients met inclusion criteria. Two patients (1.9%) ultimately supplemented ATAD with a T2 biologic. The mean outcomes measure test score after 6 months of ATAD for patients who received biologics was 40.5 versus 15 in those who did not receive biologics (p = 0.02). The mean differences between the postoperative predesensitization test score and the 6-month postdesensitization test score for patients who went on to receive biologics was an increase of 13 versus a decrease of 10 for those patients who did not receive biologics (p = 0.12). Conclusion: ESS, coupled with AD and ATAD, was successful in the long-term management of the majority of the patients with AERD, which rarely required the incorporation of T2 biologics. Patient questionnaires, such as outcomes measure test score, may identify aspirin therapy failures and help guide the practitioner in deciding when to introduce T2 biologics into the patient's treatment regimen.

7 November 2023 in The Laryngoscope
Verified
Journal Article
Open access
STSiddhant H. Tripathi
Siddhant H. Tripathi
SMSusie Min
Susie Min
ACAlexander S. Cody
Alexander S. Cody
GSGeet Shukla
Geet Shukla
FHFiras A. Houssein
Firas A. Houssein
Ahmad SedaghatAhmad Sedaghat
Ahmad Sedaghat
Objective: Best practices for calculation of the minimal clinically important difference (MCID) of outcome measures include the use of complementary methodologies (broadly classified as anchor‐based and distribution‐based) and reporting of the MCID's predictive ability. We sought to determine MCID calculation and reporting patterns within the otolaryngology literature.Methods: A systematic search strategy of Embase, PubMed, and Web of Science databases was developed and implemented to identify studies reporting the determination of an MCID for an outcome measure. Studies specifically within the otolaryngology literature (defined as journals classified as “otorhinolaryngology” in the Journal Citation Reports database) were included. All those journals were additionally searched for relevant articles.Results: There were 35 articles that met the inclusion criteria. Of these studies, 88.6% reported MCID of a patient‐reported outcome measure and the remainder were for objective outcome measurements. Anchor‐based methods were used by 82.9% of studies and distribution‐based methods were used by 68.6% of studies. Of all studies, 31.4% utilized anchor‐based methods alone, 17.1% utilized distribution‐based methods alone, and 51.4% used both methods. Only 25.7% of studies reported the sensitivity (median: 60.8%, range: 40.5%–86.7%) and specificity (median: 80.4%, range: 63.5%–88.0%) of the MCID to detect patients experiencing clinically important change.Conclusion: Deviation from best practices in MCID calculation and reporting exists within the otolaryngology literature, with almost half of all studies only using one method of MCID calculation and almost three‐quarters not reporting the predictive ability (sensitivity/specificity) of the calculated MCID. When predictive ability is reported, however, MCIDs appear to be more specific than sensitive.Level of Evidence: NA Laryngoscope, 134:2059–2069, 2024

24 August 2024 in The Laryngoscope
Verified
Journal Article
Open access
AAArash Abiri
Arash Abiri
EHEllen M. Hong
Ellen M. Hong
KDKatelyn K. Dilley
Katelyn K. Dilley
TNTheodore V. Nguyen
Theodore V. Nguyen
MSMandy K. Salmon
Mandy K. Salmon
Edward C KuanEdward C Kuan
Edward C Kuan
Objectives: There is growing interest in assessing patient quality of life (QOL) following treatment of sinonasal tumors, including inverted papilloma (IP). We aimed to elucidate the natural history of postoperative QOL outcomes in IP patients treated with surgery.Methods: Cases of sinonasal IP treated surgically at 4 tertiary academic rhinology centers were retrospectively reviewed. SNOT‐22 scores were used to evaluate QOL preoperatively and postoperatively (1, 3, 6, 12 months). Repeated‐measures ANOVA assessed for differences in mean scores over time. Linear regression identified factors associated with QOL longitudinally.Results: 373 patients were analyzed. Mean preoperative SNOT‐22 score was 20.6 ± 20.4, which decreased to 16.3 ± 18.8 (p = 0.041) and 11.8 ± 15.0 (p < 0.001) at 1 and 3 months postoperatively, respectively. No further changes in SNOT‐22 scores occurred beyond 3 months postoperatively (p > 0.05). When analyzed by SNOT‐22 subdomains, nasal, sleep, and otologic/facial subdomain scores (all p < 0.05) demonstrated improvement at 12‐month follow‐up compared with preoperative scores; this was not observed for the emotional subdomain score (p = 0.800). Recurrent cases were associated with higher long‐term SNOT‐22 scores (β = 7.08; p = 0.017). Age, sex, degree of dysplasia, prior surgery, primary site, and smoking history did not correlate with symptoms (all p > 0.05).Conclusions: QOL outcomes related to IP resection are largely driven by nasal, sleep, and otologic/facial subdomains, though patients appear to experience enduring improvement as early as 3 months postoperatively. Recurrent disease is a major driver of negative QOL.Level of Evidence: 4 Laryngoscope, 135:579–585, 2025

24 August 2026 in Laryngoscope Investigative Otolaryngology
Verified
Journal Article
Open access
PDF file
CLChristine Lee
Christine Lee
ENEmma Nienaber
Emma Nienaber
ABAdam Beucler
Adam Beucler
STSiddhant Tripathi
Siddhant Tripathi
NHNicholas Hutchins
Nicholas Hutchins
YPYash Patil
Yash Patil
Objective: To compare perioperative management and clinical outcomes of patients undergoing head and neck free flap reconstruction before and during the COVID‐19 pandemic. Methods: Retrospective cohort study of 220 patients who underwent microvascular free flap reconstruction by a single surgeon at a tertiary academic medical center. Perioperative practices and postoperative outcomes, including length of stay, wound infection, complications, two‐year survival, and recurrence, were compared between cohorts. Poisson regression with robust error variance was used to calculate adjusted relative risks (RRs). Results: Demographic and baseline oncologic characteristics were largely similar between cohorts. During the pandemic, patients were less likely to undergo intraoperative tracheostomy and PEG placement. Regression analysis showed the pandemic period was independently associated with increased wound infection risk and reduced recurrence. Conclusions: Head and neck free flap reconstruction remained safe during the COVID‐19 pandemic, with stable cancer outcomes despite shifts in perioperative practice. However, the higher risk of wound infection highlights the need for targeted preventive strategies during times of healthcare disruption.